Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Marjo Pajunen"'
Autor:
Petri Bono, Marjo Pajunen, Pirkko-Liisa Kellokumpu-Lehtinen, Raija Asola, Paula Poikonen, R. Kokko, Henrik Lindman, Päivi Auvinen, Vesa Kataja, Riikka Huovinen, Minna Tanner, Arja Jukkola-Vuorinen, Paul Nyandoto, M. Leinonen, Heikki Joensuu, Outi Paija, Kenneth Villman, Leena Helle, Johan Ahlgren, Greger Nilsson
Publikováno v:
Journal of Clinical Oncology. 30:11-18
Purpose Capecitabine is an active agent in the treatment of breast cancer. It is not known whether integration of capecitabine into an adjuvant regimen that contains a taxane, an anthracycline, and cyclophosphamide improves outcome in early breast ca
Autor:
Tuomo Alanko, Jorma Isola, Kari Möykkynen, Pirkko-Liisa Kellokumpu-Lehtinen, Petri Bono, Hannu Leinonen, Tapio Utriainen, Päivi Auvinen, T. Salminen, Raija Asola, Leena Helle, Vesa Kataja, Taina Turpeenniemi-Hujanen, Sirkku Jyrkkiö, Marjo Pajunen, Mauri Huusko, Seija Ingalsuo, R. Kokko, Heikki Joensuu, M. Leinonen
Publikováno v:
Journal of Clinical Oncology. 27:5685-5692
Purpose Docetaxel has not been compared with vinorelbine as adjuvant treatment of early breast cancer. Efficacy and long-term safety of a short course of adjuvant trastuzumab administered concomitantly with chemotherapy for human epidermal growth fac
Publikováno v:
Acta Medica Scandinavica. 216:323-326
Vascular symptoms after vinca-alcaloids and bleomycin are known. We report a 50-year-old woman who was cigarette smoker and who had had the syndrome of Raynaud's phenomenon for two years before she developed non-Hodgkin lymphoma. She was treated with
Autor:
Arja Jukkola-Vuorinen, Paula Poikonen, Raija Asola, Paul Nyandoto, Lauri Nuortio, Minna Tanner, Kenneth Villman, Marjo Pajunen, Johan Ahlgren, Outi Paija, Pirkko-Liisa Kellokumpu-Lehtinen, Akseli Hemminki, Riikka Huovinen, R. Kokko, Vesa Kataja, Leena Helle, Heikki Joensuu, Petri Bono, Henrik Lindman, Päivi Auvinen, Sirpa-Liisa Lahtela, Greger Nilsson, Kaisa Lehtiö, M. Leinonen
Publikováno v:
The Lancet. Oncology. 10(12)
Standard adjuvant chemotherapy regimens for patients with moderate-to-high-risk early breast cancer typically contain a taxane, an anthracycline, and cyclophosphamide. We aimed to investigate whether integration of capecitabine into such a regimen en
Autor:
M. Leinonen, Mervi Rauhala, Marjo Pajunen, Tapio Utriainen, Raija Asola, Anna-Stina Jääskeläinen, Pirkko-Liisa Kellokumpu-Lehtinen, R. Kokko, Seija Ingalsuo, Maija Tarkkanen, T. Salminen, Akseli Hemminki, Inkeri Elomaa, Tuomo Alanko, Petri Bono, Kaisu Johansson, Vesa Kataja, Martti Flander, Jorma Isola, Leena Helle, Jaana Kaleva-Kerola, Sirkku Jyrkkiö, Taina Turpeenniemi-Hujanen, Heikki Joensuu
Publikováno v:
The New England journal of medicine. 354(8)
We compared docetaxel with vinorelbine for the adjuvant treatment of early breast cancer. Women with tumors that overexpressed HER2/neu were also assigned to receive concomitant treatment with trastuzumab or no such treatment.We randomly assigned 101
Autor:
Sandra Legault, Ian E. Smith, Eugene V. McCloskey, A. Tidy, Marjo Pajunen, Lars Ottestad, Liisa Pylkkänen, Auli Nevantaus, Jaakko Nevalainen, Kirsi Rosenqvist, Trevor J. Powles, Sue Ashley, Anne Suovuori, Esa Männistö, Sari Atula, Sandy Paterson, John A. Kanis
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 20(15)
PURPOSE: The development of bone metastases depends on tumor-induced osteoclastic resorption of bone, which may be inhibited by the antiosteolytic bisphosphonate clodronate. Given to patients with primary breast cancer, clodronate might reduce the su
Publikováno v:
Cancer chemotherapy and pharmacology. 36(3)
A total of 23 patients with metastatic sarcomas were treated with continuous oral trofosfamide, an alkylating agent structurally related to cyclophosphamide and ifosfamide. In all, 12 of the patients were chemotherapy-naive. Doses were escalated ever